ClinicalTrials.gg
Active, not recruitingNCT07142811Updated Nov 17, 2026

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

A Phase 2 interventional study of Tobevibart and Elebsiran in Viral Hepatitis, sponsored by Vir Biotechnology, Inc.. Active, not recruiting at 27 sites in 11 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Vir Biotechnology, Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 17, 2026Primary completion movedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 40 studies in Hepatitis with a site in France — 7 open to participants now, 10 under way, 1 of them phase 3. Hepatitis · France.

Planned enrollment
19th of 27
100 · median 230
Started
2025
with 3 others
Phase 2
7 of 40
1 open now
Registered
38th of 40
by date
Lead sponsor
4 of 40
Vir Biotechnology, Inc.

Among the 40 studies in Hepatitis with a site in France, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 in phase 2, and was the 38th registered.

Hepatitis

344 studies on the registry are indexed under Hepatitis; 52 are open to participants now.

Browse Hepatitis studies →

Open to participants now

7 of the 40 studies in Hepatitis with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Hepatitis with a site in France, or all of them as a file.
02

Study summary

A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection

03

Conditions studied

  • Viral Hepatitis

Keywords

  • HDV
  • Hepatitis D Virus
  • Hepatitis
  • Chronic Hepatitis D Virus
  • Hepatitis D
  • Hepatitis D, Chronic
  • Hepatitis Delta Virus
  • Digestive System Diseases
  • Liver Diseases
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ages 18 to 70 years at screening
  2. Positive HDV antibody or positive HDV RNA PCR result for at least 6 months prior to screening and HDV RNA ≥ 500 IU/mL at screening
  3. Noncirrhotic or compensated cirrhotic liver disease at screening
  4. On NRTI therapy against for at least 12 weeks prior to day 1 or have HBV DNA \< 10 IU/ml at screening, currently on locally approved NRTI therapy

Exclusion criteria

Exclusion Criteria:

  1. Serum ≥ 5 ×
  2. Any chronic or acute medical or psychiatric condition that makes the participant unsuitable for participation.
  3. History of significant liver disease from non- or non-HDV etiology
  4. History of allergic reactions, , or intolerance to study drug, its metabolites, or .
  5. History of anaphylaxis
  6. History of immune complex disease
  7. History of disorder
  8. Current therapy or therapy within 24 weeks of screening with an immunomodulatory agent, , , cytotoxic or chemotherapeutic agent, or chronic systemic .
  9. Any previous treatment with Bulevirtide
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Participants will receive treatment with tobevibart + elebsiran up to 240 weeks.

    Drug: Tobevibart · Drug: Elebsiran

  • Experimental
    Arm 2

    Participants will receive Bulevirtide for approximately 48 weeks and switch to receive tobevibart + elebsiran for additional 192 weeks

    Drug: Tobevibart · Drug: Elebsiran · Drug: Bulevirtide

Interventions

  • Tobevibart administered by subcutaneous injection

    Also known as: VIR-3434

  • Elebsiran administered by subcutaneous injection

    Also known as: VIR-2218

  • Bulevirtide administered by subcutaneous injection

    Also known as: Hepcludex

06

What researchers measure

Primary outcomes

  1. HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48

    Time frame: Week 48

  2. HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatment

    Time frame: 24 Weeks after End of Treatment

  3. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 48

    Time frame: Week 48

Secondary outcomes

  1. HBsAg < 10 IU/mL at Week 48

    Time frame: Week 48

  2. Change from baseline in HDV RNA at Week 48

    Time frame: Week 48

  3. Change from baseline in ALT at Week 48

    Time frame: Week 48

  4. HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 96, Week 144, Week 168, Week 192 and Week 240

    Time frame: Week 96, Week 144, Week 168, Week 192 and Week 240

  5. Change from baseline in HDV RNA at Week 96, Week 144, Week 168, Week 192 and Week 240

    Time frame: Week 96, Week 144, Week 168, Week 192 and Week 240

  6. Change from baseline in ALT at Week 96, Week 144, Week 168, Week 192 and Week 240

    Time frame: Week 96, Week 144, Week 168, Week 192 and Week 240

07

Study locations

27 sites
  • Investigative Site
    Brussels, 1020, Belgium
  • Investigative Site
    Brussels, 1070, Belgium
  • Investigative Site
    Edegem, 2650, Belgium
  • Investigative Site
    Sofia, 1407, Bulgaria
  • Investigative Site
    Sofia, 1431, Bulgaria
  • Investigative Site
    Stara Zagora, 6003, Bulgaria
  • Investigative Site
    Clichy, 92110, France
  • Investigative Site
    Créteil, 94000, France
  • Investigative Site
    Limoges, 87042, France
  • Investigative Site
    Rennes, 35000, France
  • Investigative Site
    Toulouse, 31059, France
  • Investigative Site
    Hanover, 30625, Germany
  • Investigative Site
    Chisinau, 2025, Moldova
  • Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Investigative Site
    Rotterdam, 3015 GD, Netherlands
  • Investigative Site
    Karachi, 74800, Pakistan
  • Investigative Site
    Karachi, 75600, Pakistan
  • Investigative Site
    Lahore, 54800, Pakistan
  • Investigative Site
    Rawalpindi, 46000, Pakistan
  • Investigative Site
    Bucharest, 030303, Romania
  • Investigative Site
    Barcelona, 08028, Spain
  • Investigative Site
    Madrid, 28064, Spain
  • Investigative
    Valencia, 46014, Spain
  • Investigative Site
    Kyiv, 01135, Ukraine
  • Investigative Site
    London, E1 1BB, United Kingdom
  • Investigative Site
    London, SE5 9RS, United Kingdom
  • Investigative Site
    Manchester, M8 5RB, United Kingdom
08

References and documents

Publications

  • Noack J, Anglero-Rodriguez Y, Gall J, Zhou J, LeBlanc S, Liebow A, Bakardjiev A, Hebner CM, Purcell LA, Jadhav V, Corti D, Lempp FA. Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models. Antimicrob Agents Chemother. 2026 Mar 4;70(3):e0112725. doi: 10.1128/aac.01127-25. Epub 2026 Jan 26. PubMed 41586499 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2029, 43 months after the start.

Of 22 phase 2 interventional studies under Hepatitis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 40. This study's planned 43 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Mar 2029, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 27, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Mar 2029was Nov 2026
CompletionEst.
Jul 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites removed
Show 4 removed
  • Investigative Site · Nijmegen, Netherlands
  • Investigative Site · Bucharest, Romania
  • Investigative Site · Bucharest, Romania
  • Investigative Site · Nottingham, United Kingdom
Nov 17, 2026
Primary completion
Nov 2026→Mar 2029
Nov 17, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedAny previous treatment with BulivertideBulevirtide
Nov 17, 2026
Secondary outcomes
3 edited, 1 added
What changed in the outcomes
  • EditedHDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 96, Week 120144, Week 144168, Week 192 and Week 240Time frame: Week 96, Week 120, Week 144, Week 192 and Week 240 → Week 96, Week 144, Week 168, Week 192 and Week 240
  • EditedChange from baseline in HDV RNA at Week 96, Week 120144, Week 144168, Week 192 and Week 240Time frame: Week 96, Week 120, Week 144, Week 192 and Week 240 → Week 96, Week 144, Week 168, Week 192 and Week 240
  • EditedChange from baseline in ALT at Week 96, Week 120144, Week 144168, Week 192 and Week 240Time frame: Week 96 to Week 120, Week 144, Week 192 and Week 240 → Week 96, Week 144, Week 168, Week 192 and Week 240
  • AddedHBsAg < 10 IU/mL at Week 48Time frame: Week 48
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    4 sites removed
    Show 4 removed
    • Investigative Site · Nijmegen, Netherlands
    • Investigative Site · Bucharest, Romania
    • Investigative Site · Bucharest, Romania
    • Investigative Site · Nottingham, United Kingdom
    Primary completion Nov 2026→Mar 2029
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedAny previous treatment with BulivertideBulevirtide
    Secondary outcomes 3 edited, 1 added
    What changed in the outcomes
    • EditedHDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 96, Week 120144, Week 144168, Week 192 and Week 240Time frame: Week 96, Week 120, Week 144, Week 192 and Week 240 → Week 96, Week 144, Week 168, Week 192 and Week 240
    • EditedChange from baseline in HDV RNA at Week 96, Week 120144, Week 144168, Week 192 and Week 240Time frame: Week 96, Week 120, Week 144, Week 192 and Week 240 → Week 96, Week 144, Week 168, Week 192 and Week 240
    • EditedChange from baseline in ALT at Week 96, Week 120144, Week 144168, Week 192 and Week 240Time frame: Week 96 to Week 120, Week 144, Week 192 and Week 240 → Week 96, Week 144, Week 168, Week 192 and Week 240
    • AddedHBsAg < 10 IU/mL at Week 48Time frame: Week 48
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07142811
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Aug 5, 2025
Primary completion
Mar 2029 (estimated)
Completion
Jul 2030 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tobevibart · Elebsiran

Start the discussion